MedTrace Logo

Gemigliptin, Dapagliflozin, Empagliflozin DDI Study

NCT03565458 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2018-06-21

No results posted yet for this study

Summary

gemigliptin,SGLT-2i DDI study

Conditions

Interventions

DRUG

Gemigliptin

zemiglo 50mg,LG Chem

DRUG

Dapagliflozin

forxiga, dapagliflozin 10mg

DRUG

Empagliflozin

jardiance 25mg, empagliflozin

Sponsors & Collaborators

  • LG Chem

    lead INDUSTRY

Principal Investigators

  • jungryul kim, doctor · samsung seoul medical center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-04-05
Primary Completion
2018-08-20
Completion
2018-12-22

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03565458 on ClinicalTrials.gov